Retinal Exudates and Hemorrhages in a Survivor of Breast Cancer

Moussa, Kareem; Kim, Janice; Miller, John B.

doi:10.1001/jamaophthalmol.2018.3794

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What cannot be ignored is that a similar etiology between tamoxifen-induced rentinopathy and MacTel2 of decreased serum estrogen concentration and functional damage of Müller cells caused similar symptoms [ 9 , 10 ]. Both of these can present CME and yellow-white deposits.…”

Section: Discussionmentioning

confidence: 99%

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

Xiao

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

Background Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing tamoxifen with the approval of the oncologist is the major treatment for cases with tamoxifen-induced retinopathy. Case presentation We herein reported a patient with a two-year history of painless and reduced visual acuity in both eyes who received tamoxifen therapy for 6 years. Tamoxifen-induced rentinopathy with CME showed significant development even though the patient has already discontinued tamoxifen treatment for 6 months. Anatomic improvements after intravitreal ranibizumab injection in both eyes were significant but were temporary. Surprisingly, CME in both eyes has been resolved spontaneously after 10 months in the penultimate visit without any therapy. Conclusion Intravitreal ranibizumab injection temporarily improved the anatomy of the eyes in a case with tamoxifen-induced CME, and only tamoxifen withdrawal can bring a sustained effect.

show abstract

Section: Discussionmentioning

confidence: 99%

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

Xiao

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Tamoxifen, an anti-oestrogen widely used in breast cancer, is associated with the occurrence of retinal exudates and haemorrhages [111][112][113] (Table 2). Some reports described sporadic cases of different types of retinal injury induced by various anticancer drugs (alkylating agents, ICIs, MAP kinase inhibitors, and anti-VEGF) [114][115][116][117][118][119][120] (Table 2).…”

Section: Retinopathymentioning

confidence: 99%

Type 2 diabetes and cancer: problems and suggestions for best patient management

Milluzzo

Vigneri

Martorana

et al. 2020

Exploration of Medicine

View full text Add to dashboard Cite

Diabetes and cancer are widespread worldwide and the number of subjects presenting both diseases increased over the years. The management of cancer patients having diabetes represents a challenge not only because of the complexity and heterogeneity of these pathologies but also for the lack of standardised clinical guidelines. The diagnosis of cancer is traumatizing and monopolizes the attention of both patients and caregivers. Thus, pre-existent or new-onset diabetes can be overshadowed thus increasing the risk for short- and long-term adverse events. Moreover, drugs used for each disease can interfere with the clinical course of the concomitant disease, making challenging the management of these patients. Over the years, this issue has become more relevant because of the increased patients’ life expectancy due to the improved efficacy of diabetes and cancer therapies. The purpose of this review is to highlight what is known and what should be taken into consideration to optimise the clinical management of patients with diabetes and cancer. Due to the complexity of these diseases, a multidisciplinary, shared approach, including all the protagonists involved, is necessary to improve patients’ quality of life and lifespan.

show abstract

Cancer drugs and diabetic retinopathy: a dangerous, underestimated association

Milluzzo,

Manuella,

Frittitta

et al. 2024

Metab Target Organ Damage

View full text Add to dashboard Cite

The worldwide growing prevalence of diabetes and cancer led to an increase in subjects affected by both these diseases that share several of the involved risk factors and have a complex, multifactorial etiopathogenesis. Cancer therapies could have harmful effects on several organs, particularly in subjects also affected by diabetes and its related comorbidities. Moreover, cancer diagnosis often monopolizes the attention of both patients and caregivers, thus reducing the attention to pre-existent diseases. Retinopathy is one of the most frequent microvascular complications of diabetes, accounting for about 5% of legal blindness worldwide. The retinal neurovascular unit is dysfunctional in diabetes and could represent a frail site when cancer therapies are administered. Nevertheless, the short- and long-term effects of the different anticancer molecules on retinal tissue, especially in diabetic subjects, are poorly known, and no specific recommendations on their prevention and management are available. In this review, we summarised the current data on this topic, focusing on the different cancer class drugs involved in retinal damage: anti-oestrogen, classical cytolytic chemotherapy (alkylating agents, taxanes, topoisomerase inhibitors, and antimetabolites), mitogen-activated protein kinase, tyrosine-kinase, and vascular endothelial growth factor inhibitors are the cancer drugs associated with retinal damage and visual disturbance. However, further studies are necessary to improve knowledge on the molecular and clinical relation between cancer therapies and retinopathy, in order to provide clinicians with evidence-based protocols to optimise the management of these conditions and minimise vision loss occurrence, impaired quality of life, and public health expense.

show abstract

Retinal Exudates and Hemorrhages in a Survivor of Breast Cancer

Cited by 4 publications

References 9 publications

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

Type 2 diabetes and cancer: problems and suggestions for best patient management

Cancer drugs and diabetic retinopathy: a dangerous, underestimated association

Contact Info

Product

Resources

About